Product nameNative Human LMW Kininogen protein
Purity> 95 % SDS-PAGE.
Protein lengthFull length protein
Our Abpromise guarantee covers the use of ab91118 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Additional notesPrepared from plasma shown to be non reactive for HBsAg, anti-HCV, anti-HBc, and negative for anti-HIV 1 & 2 by FDA approved tests.
Concentration information loading...
Preparation and Storage
Stability and Storage
Shipped at 4°C. Store at -20ºC.
Constituents: 0.082% Sodium acetate, 1.16% Sodium chloride
- Alpha-2-thiol proteinase inhibitor
Function(1) Kininogens are inhibitors of thiol proteases; (2) HMW-kininogen plays an important role in blood coagulation by helping to position optimally prekallikrein and factor XI next to factor XII; (3) HMW-kininogen inhibits the thrombin- and plasmin-induced aggregation of thrombocytes; (4) the active peptide bradykinin that is released from HMW-kininogen shows a variety of physiological effects: (4A) influence in smooth muscle contraction, (4B) induction of hypotension, (4C) natriuresis and diuresis, (4D) decrease in blood glucose level, (4E) it is a mediator of inflammation and causes (4E1) increase in vascular permeability, (4E2) stimulation of nociceptors (4E3) release of other mediators of inflammation (e.g. prostaglandins), (4F) it has a cardioprotective effect (directly via bradykinin action, indirectly via endothelium-derived relaxing factor action); (5) LMW-kininogen inhibits the aggregation of thrombocytes; (6) LMW-kininogen is in contrast to HMW-kininogen not involved in blood clotting.
Tissue specificitySecreted in plasma. T-kinin is detected in malignant ovarian, colon and breast carcinomas, but not in benign tumors.
Involvement in diseaseDefects in KNG1 are the cause of high molecular weight kininogen deficiency (HMWK deficiency) [MIM:228960]. HMWK deficiency is an autosomal recessive coagulation defect. Patients with HWMK deficiency do not have a hemorrhagic tendency, but they exhibit abnormal surface-mediated activation of fibrinolysis.
Sequence similaritiesContains 3 cystatin kininogen-type domains.
modificationsBradykinin is released from kininogen by plasma kallikrein.
Hydroxylation of Pro-383 occurs prior to the release of bradykinin.
Phosphorylation sites are present in the extracellular medium.
N- and O-glycosylated. O-glycosylated with core 1 or possibly core 8 glycans.
Cellular localizationSecreted > extracellular space.
- Information by UniProt
Lane 1 : Anti-LMW Kininogen antibody (ab79650) at 1/100 dilution
Lane 2 : Coomassie Blue staining
All lanes :
Native Human LMW Kininogen protein (ab91118)
Lysates/proteins at 0.01 µg per lane.
All lanes : HRP-conjugated goat anti-rabbit monoclonal at 1/1000 dilution
Developed using the ECL technique.
Exposure time: 20 minutes
Blocked with 5% non-fat milk for 15 hours at 4°C
To our knowledge, customised protocols are not required for this product. Please try the standard protocols listed below and let us know how you get on.
ab91118 has not yet been referenced specifically in any publications.